Nanosyn, Inc. and PCAS Announce the Signing of a Joint-Venture Agreement to Operate PCAS-NANOSYN
LONGJUMEAU, PARIS and MENLO PARK, Calif., Aug. 12 /PRNewswire/ -- PCAS, a worldwide leader in commercial scale pharmaceutical synthesis and fine and specialty chemical manufacturing, and Nanosyn, a leading US based pharmaceutical contract research provider of preclinical chemistry and biology services, announce the signing of a joint-venture agreement to operate PCAS-NANOSYN, LLC, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California.
The newly created company, PCAS-NANOSYN, LLC, will enable PCAS and Nanosyn to satisfy a broader range of customer needs in the pharmaceutical and biotech marketplaces by offering fully integrated custom chemical services from discovery to commercialization.
"The formation of this JV with such a reputable partner as we have found in Nanosyn allows us to place critical preclinical and clinical trial API synthetic capabilities nearer to our clients in the US," said Christian Moretti, Chairman of PCAS, "It is an ideal next step in our strategy to continue growing our customer base in North America and builds on the success of our PCAS America marketing office in New Jersey."
The joint venture operation will provide services out of an FDA inspected facility in Santa Rosa, California, housing six (GMP) suites, two of which are certified as Class 10,000 clean rooms. PCAS-NANOSYN, LLC customers will further benefit from the significant chemical and analytical resources within the parent companies, and the ability to seamlessly transfer projects for larger scale to PCAS' network of four FDA inspected pilot and commercial scale plants in Europe.
"We are excited to offer this suite of cGMP solutions as a result of this partnership. For our clients, this is a natural extension of Nanosyn's highly successful discovery services into process development, scale-up, and supply of preclinical and cGMP clinical trial quantities of APIs," said Nikolai Sepetov, President and CEO of Nanosyn, Inc. "Ensuring quality, start to finish, is fundamental to the success we share with our clients."
Currently, the PCAS-NANOSYN, LLC facility is fully operational and is founded on the assets of Seres Laboratories. Nanosyn acquired the physical assets of Seres in March of 2009 and retained its experienced staff in order to take advantage of its 30 year history as an FDA registered cGMP site. As part of PCAS-NANOSYN, LLC strategy to be the premier provider of high quality and cost efficient services for the pharmaceutical and biotechnology industries, the joint venture plans to expand the site by upgrading its existing R&D and analytical capabilities, while adding new, advanced capacities. Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc., will serve as CEO of the newly formed company.
Nanosyn (www.nanosyn.com) is a Contract Research Organization providing integrated drug discovery services, medicinal chemistry, made-to-order focused compound libraries, hit-to-lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in Menlo Park, California with sites in San Diego, California and Research Triangle Park, North Carolina.
PCAS (www.pcas.com) is a listed group on the Paris Stockmarket. A leading Fine Chemical company, PCAS operates eight chemical plants in Europe and North America and offers world-class services related to the process development and manufacturing of multi-step, complex organic chemicals from kilolab to multi-ton scale. PCAS provides services for the pharmaceutical, flavor and fragrance, cosmetic, and industrial market sectors.